Life Science Investing Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Life Science Investing Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Life Science Investing Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Homerun Resources Inc. Receives Conditional Approval from the TSXV for $6 Million Financing with Institutional Investor
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
